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Urolithiasis is a worldwide problem with significant health
and economic burdens. Medical therapy that alters the
course of stone disease has enormous medical and financial
impact. Urolithiasis is a final manifestation of a broad range
of etiologies and pathogenesis. The modest progress in
understanding the pathophysiology has hampered successful
development of targeted therapy. Current regimens are
based mostly on rational alteration of urinary biochemistry
and physical chemistry to lower the risk of precipitation. In
terms of pharmacotherapy, there are drugs to successfully
improve hypercalciuria, hypocitraturia, aciduria,
hyperuricosuria, and hypercystinuria. These agents have
been proven to be effective in randomized controlled trials
in improving urinary biochemical and physicochemical risk
factors, as well as clinical outcomes. Although our current
regimens have clearly improved the management and
lives of stone formers, there are still clearly identifiable
immense voids in the knowledge of pathophysiology
of stone disease that can be filled with combined basic
science and clinical studies.
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Urolithiasis is a global problem spanning all geographic
regions with an estimated annual incidence of 1%, prevalence
of 3–5% and a lifetime risk of 15–25%. Once afflicted,
urolithiasis tends to be recurrent in the majority of cases.
According to data from the Urological Diseases in America
Project, the total annual cost of nephrolithiasis in the United
States in the year 2000 was about $5.3 billion. This
underscores the toll taken by this disease on working-age
individuals and society at large. Given the high cost of urgent
medical treatment and/or surgical intervention, the attrac-
tiveness of a medical prophylactic program to reduce stone
occurrences or increase the likelihood of successful con-
servative management of an acute-stone event is obvious.
Indeed, simple medical management strategies utilizing
inexpensive drug therapies have been shown to be efficacious
and cost effective.1 A retrospective study of patients followed
for up to 20 years has shown sustained efficacy of medical
therapy in the improvement of biochemical parameters and
clinical events.2
Although there is steady improvement in therapy with
shock-wave therapy and endourological techniques, the
advance of medical therapy has been rather modest. From
an etiological and pathophysiological point of view, it is
important to emphasize that urolithiasis is a mere final
manifestation of diverse and systemic etiological and
pathogenic events. A major hurdle in this field in the past
and present is the fact that the development of specific
targeted therapy has been handicapped by the relative slow
progress in unraveling pathophysiology. Current medical
approaches are based on carefully constructed and rational
modification of urinary biochemistry and physical chemistry
to lower stone risk rather than etiology. This brief review is
not meant to discuss the pathophysiology of urolithiasis, but
rather provides a summary of the existing clinical data on
medical therapy. Prospective randomized controlled trials
will be highlighted, whereas uncontrolled and retrospective
studies will be mentioned. Dietary and life style modifica-
tions and surgical therapy are not covered in this review.
Because of the space limitation, complete and exhaustive
citation is not possible.
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MEDICAL EXPULSIVE THERAPY (MET)
One area in which medical therapy alters the natural history
of stone disease is on the spontaneous passage of ureteral
calculi. The two most important factors in predicting the
ureteral stone passage are stone size and location. A meta-
analysis of observational studies showed spontaneous passage
rates of 12, 22, and 45% for proximal, middle, and distal
ureteral calculi, respectively, and 55, 35, and 8% for stones
o4, 4–6, and 46 mm, respectively.3 However, even stones
that eventually pass may do so with debilitating pain over an
unpredictable time interval. Consequently, agents that
promote spontaneous stone passage and reduce the symp-
toms associated with passage are needed.
Corticosteroids, hormones, nonsteroidal anti-inflamma-
tory agents, calcium-channel blockers and a-adrenergic
blockers have been evaluated. Calcium-channel blockers
and a-blockers have emerged as the most promising agents
for MET. Calcium-channel blockers suppress smooth muscle
contraction and reduce ureteral spasm, whereas a-1 adre-
nergic receptor antagonists decrease ureteral smooth muscle
tone and frequency and force of peristalsis.4–5
A meta-analysis of nine randomized clinical trials (RCTs)
compared calcium-channel blockers or a-blockers, with or
without corticosteroids, against placebo or no treatment.6
Patients treated with MET had a 65% greater likelihood of
spontaneous stone passage than the control group (pooled
risk ratio 1.65, 95% confidence interval (CI) 1.45–1.88, Po0.0001).
Efficacy was demonstrated for both calcium-channel blockers
(risk ratio 1.90, 95% CI 1.51–2.40, Po0.001) and a-blockers
(risk ratio 1.54, 95% CI 1.29–1.85, Po0.001). The additional
benefit of corticosteroids with either calcium-channel blockers
or a-blockers was modest. One small RCT directly compared
tamsulosin vs tamsulosin plus corticosteroid and showed no
difference in stone passage rates, but the corticosteroid group
passed their stones on average 2 days sooner.7
A meta-analysis of 11 RCTs (911 patients) reported a 44%
higher likelihood of spontaneous stone passage with a-
blockers compared with no treatment (risk ratio 1.44, 95% CI
1.31–1.59, Po0.001).8 The combined American Urological
Association/European Urological Association 2007 Ureteral
Stones Clinical Guidelines Panel evaluated all available MET
trials and determined that a-blockers resulted in a 29% (95%
CI 20–37) absolute increase in stone passage rate, whereas
calcium-channel blockers showed only a statistically non-
significant 9% (95% CI 7–25) improvement from no
treatment.9 The predominance of a1D-receptor subtypes in
the distal ureter and detrusor suggests selective antagonists
may have superior efficacy, but there is no data to date to
support this claim.10–12
The combined American Urological Association/European
Urological Association Ureteral Stones Clinical Guidelines
Panel recommended that for patients with newly diagnosed
ureteral stone o10 mm and well-controlled symptoms MET
should be prescribed.9 There is good evidence to support the
use of MET for patients witho10 mm distal ureteral calculi.
Because of its low cost and high safety profile, prevention of
even a single surgical intervention more than compensates
for the cost of MET.
Some questions still remain. Most RCTs tested patients
with distal ureteral calculi. It is not clear whether the results
can be extrapolated to patients with proximal and middle
ureter stones. The role of corticosteroids is still uncertain.
Finally, the optimal MET regimen with regard to agent(s),
dosage, duration, and patient selection await further large-
scale multicenter randomized trials. A summary of the
various MET treatments is shown in Table 1.
HYPERCALCIURIA
At present, the only medical therapy directed at reducing
urinary calcium is thiazide diuretics. The efficacy of thiazide
on recurrent calcium-stone formation has been tested in six
RCTs.13–18 In four of these studies spanning a total of nearly
460 patient-years, thiazide diuretics significantly decreased
stone recurrence.15–18 The stone-forming populations studied
were heterogeneous and hypercalciuria was reported in
20–100% of the study subjects in three studies.15–16,18 Sub-
group analyses were not made between hypercalciuric and
normocalciuric kidney stone populations to discern whether
the treatment is more beneficial in one group. In one study, a
‘non-selective’ approach was advocated in the prophylaxis of
the renal stones as long as secondary causes, such as renal
tubular acidosis, enteric hyperoxaluria, hypercalcemic dis-
orders, and urinary tract infections, are excluded.16 In studies
in which pre-treatment data were available, stone events were
decreased simply by enrollment into a trial highlighting the
importance of general medical care.
In contrast, two RCTs conducted over a total of 75
patient-years concluded thiazide is ineffective in reducing
kidney stone incidence.13–14 The negative outcomes may in
Table 1 | Commonly used drugs in medical expulsive therapy
Drug
Type Generic name Trade name
Recommended
dosage
Calcium-channel
blocker
Nifedipine Adalat
Adalat CC
Procardia
Procardia XL
30mg/day
a1-Selective
a-blocker
Tamsulosin Flomax
Flomaxtra
Urimax
0.4mg/day
a1-Selective
a-blocker
Terazosin Hytrin 5mg/day
a1-Selective
a-blocker
Doxazosin Cardura 4mg/day
Corticosteroid Deflazacort Calcort
Cortax
Decortil
Deflanil
30mg/day
Glucocorticoid Methylprednisolone Medrol
A-methaPred
Depo-Medrol
Medrol DosePak
Solu-Medrol
16mg/day
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part be due to smaller sample size and shorter duration of
treatment. Moreover, contrary to the studies cited above,15–18
fluid intake and dietary restrictions were not controlled.13–14
As thiazide-induced hypokalemia was not present, the
negative response in these studies is unlikely due to
hypokalemia-induced hypocitraturia.
The results of the RCTs were consistent with open studies
totaling over 6600 patient-years of thiazide treatment for
calcium nephrolithiasis.19–25 Hydrochlorothiazide at 50 mg
twice a day lowered stone incidence in normocalciuric kidney
stone formers.26 Coe et al. reported new stone formation in
only 2 out of 37 patients with idiopathic hypercalciuria on
trichlormethiazide (4 mg/day) over a total of 740 patient
months of treatment24 and showed that thiazide and/or
allopurinol drastically reduced new stone formation in
recurrent calcium-stone formers with hypercalciuria and/or
hyperuricosuria over 625 patient-years.20 Over 88 patient-
years, bendroflumethiazide (2.5 mg/day) reduced new stone
formation compared with the pre-treatment phase.25 Pak
et al. segregated hypercalciuria into predominantly intestinal
hyperabsorption or renal leak and noted a decline in stone
formation rate from 2.1 to 0.40 in both groups of patients.23
In a 5-year experience with hydrochlorothiazide (50 mg/day)
and amiloride (5 mg/day) in 519 patients with recurrent
calcium nephrolithiasis, where 65% of which were classified
as hypercalciuric, 53 new stones were formed in the treated
group in contrast to the predicted 916 stones.22 A summary
of these trials are illustrated in Table 2.
The incidence of side effects on thiazide diuretics is
approximately 30% although side effects necessitating
Table 2 |Major clinical trial in pharmacotherapy of urolithiasis
Author (ref.) Drug N Design Finding
Renal colic Hollingsworth et al.6 a-Blocker or calcium-channel
blockers vs placebo or no Rx
Meta-analysis Improved likelihood of
stone passage
Parsons et al.8 a-Blocker vs no Rx 911 Meta-analysis Improved likelihood of
stone passage
Hypercalciuria Brocks et al.13 Bendroflumethiazide vs placebo 62 RCT Both groups showed decrease
in stone formation
Scholz et al.14 Hydrochlorothiazide vs placebo 51 RCT Thiazides decreased calciuria
but not stone events
Laerum and Larsen15 Hydrochlorothiazide vs placebo 50 RCT Decreased new stone formation
Prolonged stone-free interval
Ettinger et al.16 Chlorthalidone vs Mg hydroxide
vs placebo
124 RCT Chlorthalidone more effective
than Mg hydroxide or placebo
in reducing stone events
Ohkawa et al.17 Trichlormethiazide vs no treatment 175 RCT Decreased calciuria and stone
formation rate
Borghi et al.18 Diet vs diet+indapamide vs
diet+indapamide+allopurinol
75 RCT Diet + pharmacotherapy better
than diet alone.
Hypocitraturia Barcelo et al.31 Potassium citrate vs placebo 57 RCT Decreased stone formation and
increased urinary citrate
Ettinger et al.32 Potassium magnesium citrate vs placebo 64 RCT Decreased stone formation
Hofbauer et al.33 Diet+sodium potassium citrate vs diet 50 RCT No difference in stone formation
Soygu¨r et al.34 Potassium citrate vs no treatment after
shockwave lithotripsy
110 RCT Decreased stone recurrence
Kang et al.35 Mix of potassium citrate, thiazide,
allopurinol vs no treatment after
percutaneous nephrolithotomy
226 NCT Decreased stone recurrence
Pak et al.36 Potassium citrate vs pretreatment in
calcium and uric acid stone formers
89 NNT Decreased stone events
Aciduria
(uric acid stones)
Pak et al.42 Potassium citrate 18 NNT Decreased stone events
Hyperuricosuria
(calcium stones)
Ettinger et al.47 Allopurinol vs placebo 60 RCT Decreased stone events
Coe20 Thiazide vs allopurinol vs both 202 RCT Decreased stone events vs
pretreatment
Cystinuria Dahlberg et al.50 D-penicillamine 89 Retrospective Decreased stone event and
dissolution of stones
Chow et al.51 D-penicillamine or
a-mercaptopropionylglycine
vs conservative Rx
16 NNT Decreased stone event
Pak et al.52 D-penicillamine or
a-mercaptopropionylglycine
vs conservative Rx
66 Retrospective Both drugs equally effective
in reducing stone events
Barbey et al.53 D-penicillamine or
a-mercaptopropionylglycine
vs conservative Rx
27 Retrospective Decreased stone events
Abbreviations: N, number of patients; NCT, non-randomized controlled trial; NNT, non-randomized non-placebo controlled trial; RCT, randomized controlled trial;
Rx, treatment.
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discontinuation are much less frequent.19 Whether long-term
thiazide has harmful effects remains to be examined in stone
formers. A meta-analysis of clinical trials in hypertensive
subjects revealed an relationship between changes in serum
glucose and potassium concentrations.27 The Antihyperten-
sive and Lipid Lowering Treatment to Prevent Heart Attack
Trial also showed increased incidence of new-onset diabetes
mellitus in patients treated with chlorthalidone compared
with amlodipine or lisinopril. The potential pathophysiolo-
gical link between thiazides and glucose intolerance is of an
unknown nature and is of concern28 and has not been
prospectively tested in kidney stone populations. Part of the
hypocalciuric effect of thiazide is due to mere volume
contraction-induced increased proximal tubule calcium
absorption. If this were true, the thiazide effect can be
achieved equally well with dietary sodium restriction without
exposure to the risk of glucose intolerance. A summary of
drug used in the treatment of hypercalciuric nephrolithiasis is
detailed in Table 3.
In a short term trial, bisphosphonates were shown to
lower urinary calcium excretion.29–30 However, no long-term
RCTs have been performed displaying the efficacy if these
agents on recurrent calcium stone-forming population.
HYPOCITRATURIA
Three randomized trials were performed in recurrent
calcium-stone formers.31–33 These were heterogeneous
populations with respect to urinary citrate excretion with
normal or low normal urinary citrate reported in two
studies,31,32 and low urinary citrate in half of the patients in
the third study.33 In two of these studies, treatment
with potassium citrate or potassium-magnesium-citrate at
30–60 mEq base/day over a total of 129 patient-years reduced
recurrent calcium-oxalate-stone formation.31,32 However,
one RCT in 25 patients over 3 years using oral sodium-
potassium-citrate (90 mEq/day) did not show efficacy
compared with high fluid intake and dietary restrictions.33
The differences between these studies may be due to the small
size and higher dosages of alkali treatment in the latter study.
A rather dramatic result was seen in one controlled study
using 60mEq potassium citrate/day in 34 patients with
residual stones 4 weeks and 56 patients free of residual
stones after shockwave lithotripsy, potassium citrate was
shown to significantly decrease the stone recurrence rate to
zero at 12 months in treated subjects compared with 28.5
stone recurrence in untreated subjects (P¼o0.05).34 In the
study by Kang et al. of 503 subjects treated for a mean
duration of 41 months (range 6–168), there was significant
and durable increase in urinary pH (5.90–6.46, Po0.0001)
and citrate (470–700 mg a day, Po0.0001), and decrease in
stone formation rate from 1.89 to 0.46 stones per year
(Po0.0001).35
This effect is compatible with results from non-
randomized studies. In hypocitraturic calcium or uric acid
urolithiasis, potassium citrate (1–4.33 years) corrected
physicochemical profiles and reduced stone formation in
98% of patients, and the need for surgical intervention for
new stone formation was totally abrogated.36 In recurrent
stone formers with hypocitraturia alone, potassium citrate
treatment increased urinary citrate and decreased the rate of
total stone formation from 0.7/year 0.13/year (Po0.005).37
In patients with hypocitraturia plus other metabolic abnor-
malities, there was a more dramatic decline in total stone
formation rate from 1.2/year compared with 0.08/year
following the treatment (Po0.05). A summary of these trials
is illustrated in Table 2.
Alkali treatment is relatively safe with minor gastrointest-
inal side effects. One potential concern is that the over-
treatment with alkali may increase the risk of calcium-
phosphate-stone formation by increasing the abundance of
monohydrogen phosphate. Although this pathophysiological
link has been proposed, it has never been studied. It is
interesting that the potassium citrate treatment in patients
with distal renal tubular acidosis and pre-existing high
urinary pH has been shown to considerably lower rather than
increase kidney stone recurrence rate.38 It is interesting that,
if one uses the JESS instead of the EQUIL program to predict
supersaturation,39 the rise in brushite saturation is not
marked upon rise in pH and that of calcium oxalate actually
falls. Although both sodium and potassium alkali treatment
are equally effective in raising urinary pH, potassium citrate
is more effective in preventing the formation of calcium
stones by attenuating urinary calcium excretion.40 Currently,
there is no data comparing pharmacological alkali therapy
against dietary manipulation of urinary citrate.
Table 3 | Commonly used drugs in the treatment of
hypercalciuric calcium nephrolithiasis
Drug
Recommended
dosage(s) Comments
Hydrochlorothiazide 50mg/day
25mg twice/
day
A single dosage is preferred
since the twice a day dosage
may cause frequent nocturia
and consequent patient
discomfort.
Chlorthalidone 25mg/day
50mg/day
Both dosages lower urinary
calcium by the same degree.
Because of its long action,
this treatment may cause
hypokalemia and hypocitraturia.
Indapamide 1.2mg/day
2.5mg/day
This treatment may have fewer
side effects that
hydrochlorothiazide, including
the rare occurrence of
hypokalemia and hypotension.
Amiloride 5mg/day This treatment is a potassium
sparing diuretic that lowers
urinary calcium, but to a lesser
degree than hydrochlorothiazide.
Amiloride/
Hydrochlorothiazide
5mg/50mg/
day
Maintains the hypocalciuric
effect of thiazide, whereas
averting the development
of severe hypokalemia.
Trichlormethiazide 2mg/day
4mg/day
This drug is not marketed
in the United States.
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URIC ACID STONES
As acidic urine pH is the most predominant factor in the
development of uric acid stones, alkalinization of the urine is
the most effective way to treat patients with uric acid
nephrolithiasis. 40,41 In patients with uric acid nephrolithiasis
(pure uric acid and mixed uric acid and calcium oxalate
stones) treated with potassium citrate at 30–80 mEq/day,
urinary pH and undissociated uric acid increased and new
stone formation decreased from 1.20 to 0.01 stones/year,40,42
Stone remission was experienced in 94% of the patients, and
group stone formation diminished by 99%. A summary of
these trials is illustrated in Table 2. Although it has not been
tested in long-term randomized trials, sodium bicarbonate
may also offer the same alkalinizing effect although this
treatment may confer an increased risk of calcium stone
formation due to sodium-induced hypercalciuria, promotion
of monosodium urate-induced calcium oxalate crystalliza-
tion, and high pH-induced calcium phosphate precipitation.
Although urinary alkalinization does not get at the root of
the pathophysiology of aciduria in uric acid stones, it is a
pragmatic and effective therapy. The initial recommended
alkali dosage is 30–40 mEq/day. A common practice is to
frequently measure 24-h urine pH and to titrate the alkaline
dose to maintain a urine pH above 6.1 but less than 7.0 to
avoid complications of calcium phosphate stones. However,
urine pH from a 24-h urine collection may not adequately
reflect the diurnal variation in urine pH during periods of
extreme acidity. Although direct urinary pH measurements
throughout the day would be impractical, pH measurements
may be performed by urinary dip-stick analysis.43,44 This may
allow for the adjustment of medication dosage as needed
throughout the day. Allopurinol at the dosage of 300 mg/day
is used when urinary uric acid excretion is higher than
600 mg/day in women and 700 mg/day in men. This
treatment should be invariably considered in patients with
hyperuricemia, including primary gout, those with inborn
errors in metabolism, myeloproliferative disorders, hemolytic
anemia, and in tumor lysis syndrome.
HYPERURICOSURIC CALCIUM NEPHROLITHIASIS
Although hyperuricosura is not usually the cause of uric acid
stones in the absence of aciduria, there is the condition of
hyperuricosuric calcium oxalate urolithiasis in which sodium
urate or uric acid contributes to the formation of calcium
oxalate stones.45,46 Calcium oxalate stone-formers with hyper-
uricosuria, but not hypercalcemia, hypercalciuria, hyperoxaluria,
or hypocitraturia will benefit from reduction of the hyper-
uricosuria. Two studies have shown that for hyperuricosuric
calcium oxalate stone-formers without other metabolic abnor-
malities, allopurinol is effective in reducing urinary uric acid
and stone recurrence compared with no treatment (Table 2).20,47
In hyperuricosuric calcium oxalate-stone formers with multiple
metabolic abnormalities, the benefit of reduction of hyper-
uricosura alone by allopurinol is less evident.48 This under-
scores the importance of pathophysiological and metabolic
evaluation with complete blood and urinary profiles.
A non-purine analog xanthine oxidase inhibitor was
recently approved for treating hyperuricemia associated with
gouty arthritis. Although shown to be effective in reducing
hyperuricemia and arthritis attacks, the effect on uricosuria
was not reported. On the basis of its mechanism of action,
one would expect hypouricosuric effects, so for patients who
cannot tolerate allopurinol, febuxostat is a plausible con-
sideration without supportive data. The use of recombinant
uricase has no proven role in the chronic management of
hyperuricosuria.
CYSTINURIA
As the pH dependency of urinary cystine solubility was
shown over half a century ago, alkali treatment has been
widely used in the management of cystinuric subjects.
However, alkali therapy alone has limited effectiveness, as a
large dose is necessary because of the high pKa of cystine
(8.5). Such highly alkaline urine can predispose the patient to
calcium phosphate stone formation thus a urinary pH of
6.5–7.0 has been recommended to achieve dissolution of
cystine. In patients with severe cystinuria (41000 mg/day),
other agents are usually required which are thiol derivatives
that split a single cystine molecule into two cysteines and
create a highly soluble disulfide compound of the drug and a
cysteine molecule.49 Dahlberg et al. first showed that new
stone recurrence, stone passage, and stone growth were
lowered when D-penicillamine (dimethyl-cysteine) was added
to conservative treatment.50 These agents do not affect the
underlying defect in cystinuria, but their use is based on rich
biochemical and physicochemical action a-mercaptopropio-
nylglycine (tiopronin) is currently the most commonly
prescribed agent for cystinuric patients. Chow et al. com-
pared the effect of conservative treatment of hydration and
alkalinization with drug treatment using D-penicillamine or
tiopronin and showed reduction of stone events from 1.6 to
0.452 per years.51 One study showed tiopronin-induced stone
remission in 63% of patients who received previous
treatment with D-penicillamine and in 71% of patients who
were naive to treatment. Stone formation rate was reduced by
81 and 94%, respectively, by tiopronin.52 Treatment with either
D-penicillamine or tiopronin significantly decreased stone event
by 32–65% when compared with conservative management
with hydration and alkali treatment.51,53 A summary of these
trials is illustrated in Table 2. However, to date no RCTs have
been performed demonstrating the superiority of medical
treatment over placebo in this population.
a-Mercaptopropionylglycine may have lower incidence of
side effects compared with D-penicillamine52 and, therefore,
is sometimes preferred, although both drugs are effective in
reducing kidney stone incidence. The thiol-containing
compound captopril has been suggested to function similarly
to reduce urinary cystine excretion,54,55 but this finding was
not reproduced by others.53,56 In summary, in mild cases of
cystinuria, judicious urinary alkalinization and fluid may
suffice but in more severe cases, a thiol agent, such as
tiopronin or D-penicillamine, should be added.
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HYPEROXALURIA
Hyperoxaluria is an equally important contributor to calcium
oxalate supersaturation as hypercalciuria. Hyperoxaluria can
result from rare monogenetic causes (primary hyperoxaluria
type 1: alanine-glyoxylate aminotransferase deficiency; type
2: glyoxylate reductase-hydroxypyruvate reductase defi-
ciency). Type 1 patients can be managed with pyridoxine.
In one study over 250 patient-years, pyridoxine reduced
hyperoxaluria, but effect on stone events were not reported.57
Patients with type 2 are unlikely to respond to pyridoxine.58
Because of its rarity, there have been no RCTs for this
condition. Unfortunately, there is currently no proven
pharmacotherapy to effectively treat the more common form
of ‘idiopathic’ hyperoxaluria present in up to 40% of stone
formers. The probiotic approach of Oxalobacter formigenes or
direct administration of recombinant oxalate decarboxylase is
still in the experimental phase with mixed results in both
humans and rodents. Although luminal oxalate degradation
will certainly lower stool oxalate, it is still unclear whether
this will lower urinary oxalate. In another short-term study,
patients with enteric hyperoxaluria were treated with
increasing dosages of a lactic acid bacteria mixture. This
study demonstrated lowered calcium oxalate supersaturation
during this treatment, mainly due to decreased urinary
oxalate excretion. However, the degree of change was not
statistically significant.59
CURRENT STATUS AND DIRECTION OF FURTHER CLINICAL
STUDIES
Despite some clear and encouraging successes we have
witnessed over the last few decades, we are poised at a
juncture where there is a dire need for development of novel
medical pharmacotherapeutics in urolithiasis both in depth
and in lateral scope. The approach of developing a universal
treatment protocol regardless of underlying pathophysiology
or even urinary chemical parameters, may have its pragmatic
attractions because of sheer simplicity, obviation of investi-
gations, and initial cost reduction. This really is not in the
best interest of the patient as potential for ineffective or even
harmful therapy is substantial. Future efforts should be
directed to refine therapy based on underlying etiology and
pathophysiology so eventually therapy can be tailored for the
individual stone former rather than population of stone
formers. This will require coordinated and simultaneous
investigations at the levels of the laboratory bench, human
metabolic investigations, and population-based clinical
research. The majority of breakthrough discoveries will no
doubt originate from the former two categories. At the
present moment and with the current database, certain
clinical trials can be very informative and will clearly improve
our existing treatment protocols. These efforts should be
multi-center-based to ensure power and shorten the duration
to completion. For such a common disease, this really should
be an achievable goal provided support is available.
As indicated above, one can systematically test therapy targeted
to known underlying pathophysiology using individualized
regimens vs non-selective blanket treatment for stone formers.
Although targeted therapy is intuitively correct, its practical
utility has not been definitively documented in the form of a
trial. One would predict that the results will favor tailored
therapy but this needs to be shown at the population level.
Such clinical evidence will provide the justification and
motivation for metabolic evaluation of all patients with
urolithiasis. Sometimes when the ideal is not possible and
realizing that there may be circumstances in some practices
in which metabolic evaluation is not realistic, which empiric
pharmacological agent(s) should one use for calcareous stones-
alkali, thiazides, or both?
There is a need for comparison between pharmacotherapy
vs dietary therapy vs both. As discussed earlier, the
hypocalciuric effect of thiazides alone needs to be compared
with dietary sodium restriction alone, and to both salt
restriction plus thiazide. Although most experts will agree
that thiazide therapy alone without sodium restriction is
unwise, it is not clear whether thiazides when added to
sodium restriction, have additional direct benefits either in
hypocalciuria and/or bone health. If the effect of thiazides is
really due solely to volume contraction, one may consider
using it as an alternative or adjuncts to dietary sodium
restriction. The long-term side effects of thiazides, particular
regarding glucose intolerance, in stone formers should also be
prospectively evaluated. It is not known whether thiazides
have a direct effect on glucose metabolism or potassium
deficiency may be the mediating culprit. Another pharma-
cological vs dietary treatment is potassium citrate vs low
protein/acid diet. One may find comparable efficacy of
pharmacological and dietary therapy in a strictly controlled
clinical trial, but adherence may be difficult to achieve with
chronic dietary changes leaving potassium alkali as the
preferred choice. Protein restriction may also be quite
different from acid neutralization because there may be
non-acid components of protein that are lithogenic.
Another study will be to test single vs combination
therapy. An empirical approach used by practitioners is that
when one therapy does not suffice, often a second drug is
tried or added. Are two drugs better than one? The intuitive
answer appears to be yes, but we really do not have clinical
data to support whether combination therapy is indeed
superior. As none of the current regimens are completely
effective, there is clearly room for further reduction of stone
events. A combination therapy of thiazide and potassium
citrate is logical from a pathophysiological viewpoint and not
necessarily contrived.
Another kind of study will be to prospectively examine the
response of stone formers who have never undergone
procedures vs those who have. Retrospective data seem to
indicate much better result with medical treatment in patients
post lithotripsy or percutaneous procedures than those without
medical treatment following non-invasive surgical intervention.
This is a most intriguing finding lending one to wonder
whether there is a fundamental difference in the pathobiology
after surgical intervention or simply patients become much
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more compliant and motivated to avoid further procedures.
As urolithiasis is a systemic disease, there is a dire need to
understand the long-term effects of pharmacotherapy on
parameters other than urinary chemistry and stone events,
such as bone health.
As current markers of kidney stone formation relies on
computer-based analysis of urine chemistry as surrogates or
stones events as long-term gold standard outcomes. One may
consider an intermediate form of physical chemical surrogate
such as crystal agglomeration and growth as an additional
read-out to improve prediction. Finally, as urolithiasis is a
systemic disease, outcomes such as insulin resistance, and
hypertension should also be targeted and examined in the
course of intervention.
There is no doubt that these efforts are costly as with all
multi-center clinical trials and should be prioritized when
resources are limiting. It is also apparent that we need further
multi-level efforts at the basic science bench, metabolic
research units, and population studies to unravel and discover
pathophysiology-directed intervention strategies. Although
urolithiasis rarely carries the grave curse of mortality of end
stage renal failure, cardiovascular disease, or neoplasm, it does
have profound impact on quality of life and unlike the
aforementioned conditions; cure of urolithiasis is not too far
in the horizon if the proper efforts are executed.
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